person · Reporting owner
Leonard Braden Michael
Disclosed activity across 17 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BUILD-A-BEAR WORKSHOP INCBBW · Entity 5717 | Former Director of the Issuer | September 28, 2017 | October 02, 2017 |
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | 10% owner | March 20, 2024 | March 25, 2024 |
| Disc Medicine, Inc.GMTX · Entity 2273 | 10% owner | October 26, 2022 | October 27, 2022 |
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | 10% owner | January 03, 2023 | January 06, 2023 |
| Metacrine, Inc.MTCR · Entity 115177 | 10% owner | December 19, 2022 | December 21, 2022 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Former 10% owner of RPHM | October 07, 2024 | October 09, 2024 |
| Orchids Paper Products CO /DETISUQ · Entity 158423 | 10% owner | April 03, 2019 | April 10, 2019 |
| Outset Medical, Inc.OM · Entity 7026 | 10% owner | October 01, 2026 | October 05, 2026 |
| ProPhase Labs, Inc.PRPH · Entity 8699 | 10% owner | September 29, 2017 | October 02, 2017 |
| RETRACTABLE TECHNOLOGIES INCRVP · Entity 7624 | 10% owner | December 29, 2022 | December 29, 2022 |
| Satsuma Pharmaceuticals, Inc.STSA · Entity 112442 | 10% owner | November 21, 2022 | November 23, 2022 |
| Talis Biomedical CorpTLIS · Entity 87664 | 10% owner | September 05, 2024 | September 09, 2024 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Former 10% owner of AVROBIO | June 20, 2024 | June 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BUILD-A-BEAR WORKSHOP INC
Report date September 28, 2017 · Filed October 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 1,281,000 |
Last balance in matching sequence
After 2017-09-29 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-09-28 · Sale · Disposed 25,000 · Balance 1,283,000 F1: Represents the sale of shares in multiple transactions, ranging in price from $9.20 to $9.25, resulting in a weighted average sale price per share of $9.2056. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F3: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2017-09-29 · Sale · Disposed 2,000 · Balance 1,281,000 F2: Represents the sale of shares in multiple transactions, at 9.20, resulting in a weighted average sale price per share of $9.20. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F3: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 142,043 |
Reported balance
Holding disclosure · report date 2017-09-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 142,043 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the sale of shares in multiple transactions, ranging in price from $9.20 to $9.25, resulting in a weighted average sale price per share of $9.2056. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
F2: Represents the sale of shares in multiple transactions, at 9.20, resulting in a weighted average sale price per share of $9.20. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
F3: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Cyteir Therapeutics, Inc.
Report date March 20, 2024 · Filed March 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P | 3,654,053 |
Reported balance
After 2024-03-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-03-20 · Purchase · Acquired 170,589 · Balance 3,654,053 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 335,000 |
Reported balance
Holding disclosure · report date 2024-03-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 335,000 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote
Disc Medicine, Inc.
Report date October 26, 2022 · Filed October 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 247,500 |
Reported balance
After 2022-10-26 transaction · row 1
1 source rowRow 1 · 2022-10-26 · Sale · Disposed 22,500 · Balance 247,500 F2: The shares were sold in multiple transactions at $2.09. |
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 5,000,000 |
Reported balance
Holding disclosure · report date 2022-10-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000,000 F1: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Explanation of Responses: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: The shares were sold in multiple transactions at $2.09.
Enliven Therapeutics, Inc.
Report date January 03, 2023 · Filed January 06, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 1,767,774 |
Reported balance
After 2023-01-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-01-03 · Sale · Disposed 1,250,000 · Balance 1,767,774 F2: This form was filed to correct the transaction date to 1/3/2023. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 230,000 |
Reported balance
Holding disclosure · report date 2023-01-03 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 230,000 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: This form was filed to correct the transaction date to 1/3/2023.
Metacrine, Inc.
Report date December 19, 2022 · Filed December 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 6,160,570 |
Last balance in matching sequence
After 2022-12-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-12-19 · Purchase · Acquired 101,384 · Balance 5,990,349 F2: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2022-12-20 · Purchase · Acquired 50,122 · Balance 6,040,471 F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 3 · 2022-12-21 · Purchase · Acquired 120,099 · Balance 6,160,570 F4: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 600,000 |
Reported balance
Holding disclosure · report date 2022-12-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 600,000 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
F4: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request.
OnKure Therapeutics, Inc.
Report date October 07, 2024 · Filed October 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHoldings of BML Investment Partners, L.P. | 345,739 |
Reported balance
After 2024-10-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-10-07 · Other · Acquired 345,739 · Balance 345,739 F1: Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 102,076 |
Reported balance
After 2024-10-07 transaction · row 2
1 source rowRow 2 · 2024-10-07 · Other · Acquired 102,076 · Balance 102,076 F3: Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure"). |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").
F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F3: Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10. On October 4, 2024 (the "Closing Date"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company ("Reneo"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo ("Merger Sub I"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo ("Merger Sub II"), and OnKure, Inc., a Delaware corporation ("Legacy OnKure").
Orchids Paper Products CO /DE
Report date April 03, 2019 · Filed April 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 1,329,963 |
Reported balance
Holding disclosure · report date 2019-04-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,329,963 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 128,000 |
Reported balance
Holding disclosure · report date 2019-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 128,000 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Outset Medical, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHoldings of BML Investment Partners, L.P. | 2,764,610 |
Last balance in matching sequence
After 2026-10-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-10-01 · Purchase · Acquired 228,334 · Balance 2,748,035 F2: The shares were purchased in multiple transactions between $2.90 and $3.85 with an average price of $3.53. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2026-10-02 · Purchase · Acquired 16,575 · Balance 2,764,610 F3: The shares were purchased in multiple transactions at an average price of $3.8758 per share. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: The shares were purchased in multiple transactions between $2.90 and $3.85 with an average price of $3.53.
F3: The shares were purchased in multiple transactions at an average price of $3.8758 per share.
ProPhase Labs, Inc.
Report date September 29, 2017 · Filed October 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 627,322 |
Reported balance
After 2017-09-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-09-29 · Sale · Disposed 1,695,305 · Balance 627,322 F1: 1. These shares were sold to the Issuer through the tender offer by the Issuer for 4,000,000 shares of its common stock. F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. These shares were sold to the Issuer through the tender offer by the Issuer for 4,000,000 shares of its common stock.
F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
RETRACTABLE TECHNOLOGIES INC
Report date December 29, 2022 · Filed December 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 688,575 |
Reported balance
After 2022-12-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-12-29 · Sale · Disposed 3,000,000 · Balance 688,575 F2: The shares were sold in one negotiated transaction at $1.60. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 387,500 |
Reported balance
Holding disclosure · report date 2022-12-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 387,500 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: The shares were sold in one negotiated transaction at $1.60.
Satsuma Pharmaceuticals, Inc.
Report date November 21, 2022 · Filed November 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,000 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Purchase · Acquired 150,000 · Balance 150,000 F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.70 to $0.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 6,440,000 |
Reported balance
Holding disclosure · report date 2022-11-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,440,000 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein
F2: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.70 to $0.73. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Talis Biomedical Corp
Report date September 05, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 248,702 |
Last balance in matching sequence
After 2024-09-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-09-05 · Purchase · Acquired 5,100 · Balance 223,702 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2024-09-06 · Purchase · Acquired 25,000 · Balance 248,702 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Tectonic Therapeutic, Inc.
Report date June 20, 2024 · Filed June 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P, | 400,355 |
Reported balance
After 2024-06-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-06-20 · Other · Acquired 400,355 · Balance 400,355 F1: Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 33,333 |
Reported balance
After 2024-06-20 transaction · row 2
1 source rowRow 2 · 2024-06-20 · Other · Acquired 33,333 · Balance 33,333 F3: Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.
F2: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F3: Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AN2 Therapeutics, Inc.
Report date June 12, 2025 · Filed June 16, 2025
Section 16 reporting ended · disclosed 2025-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHolding of BML Investment Partners, L.P. | 3,017,432 |
Reported balance
After 2025-05-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-28 · Sale · Disposed 200,000 · Balance 3,017,432 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
ASTROTECH Corp
Report date October 03, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHoldings of BML Investment Partners, L.P | 0 |
Reported balance
After 2025-10-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-10-03 · Sale · Disposed 220,410 · Balance 0 F2: The shares were sold in multiple transactions at an average price of $7.1305. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-03 transaction · row 2
1 source rowRow 2 · 2025-10-03 · Sale · Disposed 9,166 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: The shares were sold in multiple transactions at an average price of $7.1305.
Aclaris Therapeutics, Inc.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHoldings of BML Investment Partners, L.P. | 13,950,000 |
Reported balance
After 2026-04-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-23 · Sale · Disposed 300,000 · Balance 13,950,000 F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Adverum Biotechnologies, Inc.
Report date December 04, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHoldings of BML Investment Partners, L.P. | 1,958,080 |
Reported balance
After 2025-12-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-12-04 · Sale · Disposed 524,560 · Balance 1,958,080 F2: Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold. F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 191,800 |
Reported balance
Holding disclosure · report date 2025-12-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 191,800 |
Filing footnotes · ownership attribution and instrument terms
F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
F2: Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2024 Filed Aug 15, 2024 00:48 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 100,487 | $1.41 | $142,008.23 |
DisclosureSEC source: 0001373604-24-000071 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,944,020 F3 · price: Purchased in multiple transactions with a weighted average price of $1.4132. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 00:48 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 171,339 | $1.39 | $238,589.56 |
DisclosureSEC source: 0001373604-24-000071 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,843,533 F2 · price: Purchased in multiple transactions with a weighted average price of $1.3925. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 05, 2024 Filed Aug 5, 2024 19:57 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 206,025 | $1.24 | $256,356.91 |
DisclosureSEC source: 0001373604-24-000060 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 14,250,000 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.2443 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 19:57 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 167,544 | $1.29 | $216,399.83 |
DisclosureSEC source: 0001373604-24-000060 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 14,043,975 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.2916 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 31, 2024 Filed Jul 31, 2024 20:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 100,000 | $1.33 | $132,640.00 |
DisclosureSEC source: 0001373604-24-000056 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 13,876,421 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3264 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:19 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | PurchaseCommon Stock | 85,800 | $7.15 | $613,470.00 |
DisclosureSEC source: 0001373604-24-000058 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,268,064 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 173,730 | $1.30 | $226,370.19 |
DisclosureSEC source: 0001373604-24-000056 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 13,776,421 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.303 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 22, 2024 Filed Jul 22, 2024 20:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 17,716 | $1.33 | $23,556.97 |
DisclosureSEC source: 0001373604-24-000052 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 13,602,691 F4 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3297per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 20:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 6,689 | $1.30 | $8,695.70 |
DisclosureSEC source: 0001373604-24-000052 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 13,584,975 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.30 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 01:16 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | PurchaseCommon Stock | 80,718 | $9.11 | $735,736.50 |
DisclosureSEC source: 0001373604-24-000049 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,182,264 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $9.114 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 130,317 | $1.30 | $169,555.45 |
DisclosureSEC source: 0001373604-24-000052 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 13,578,286 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3011 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 01:16 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | PurchaseCommon Stock | 135,546 | $7.75 | $1,049,925.76 |
DisclosureSEC source: 0001373604-24-000049 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,101,546 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $7.7459 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 05, 2024 Filed Jul 5, 2024 18:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 123,017 | $1.15 | $141,334.23 |
DisclosureSEC source: 0001373604-24-000045 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 13,447,969 F4 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1489per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 03, 2024 Filed Jul 5, 2024 18:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 143,288 | $1.16 | $166,070.79 |
DisclosureSEC source: 0001373604-24-000045 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 13,324,952 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.159 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 18:46 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 86,092 | $1.14 | $98,489.25 |
DisclosureSEC source: 0001373604-24-000045 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 13,181,664 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.144 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 107,434 | $1.14 | $122,184.69 |
DisclosureSEC source: 0001373604-24-000042 · form4.xml · nonDerivative · entry 4 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 13,095,572 F4 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1373per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 400,000 | $1.13 | $452,000.00 |
DisclosureSEC source: 0001373604-24-000042 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 12,988,134 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 801,000 | $1.12 | $896,559.30 |
DisclosureSEC source: 0001373604-24-000042 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 12,588,134 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1193 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 235,000 | $1.15 | $271,331.00 |
DisclosureSEC source: 0001373604-24-000042 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 11,787,134 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1546 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 17:42 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | OtherCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001373604-24-000039 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · Former 10% owner of AVROBIO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 F3 · price: Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 17:42 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | OtherCommon Stock | 400,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001373604-24-000039 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · Former 10% owner of AVROBIO 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P, Disclosed balance after: 400,355 F1 · price: Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. F2 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 18, 2024 Filed Jun 18, 2024 20:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 50,000 | $1.13 | $56,505.00 |
DisclosureSEC source: 0001373604-24-000037 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 11,552,134 F4 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1301per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 150,000 | $1.13 | $169,500.00 |
DisclosureSEC source: 0001373604-24-000037 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 11,502,134 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.13 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 345,000 | $1.17 | $402,201.00 |
DisclosureSEC source: 0001373604-24-000037 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 11,352,134 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1658 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 500,000 | $1.15 | $575,000.00 |
DisclosureSEC source: 0001373604-24-000035 · form4.xml · nonDerivative · entry 4 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 11,007,134 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 28,621 | $1.14 | $32,756.73 |
DisclosureSEC source: 0001373604-24-000035 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 10,507,134 F3 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1445 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 82,579 | $1.14 | $94,140.06 |
DisclosureSEC source: 0001373604-24-000035 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 10,478,513 F2 · price: Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.14 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 1,000,000 | $1.08 | $1,080,000.00 |
DisclosureSEC source: 0001373604-24-000035 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 10,395,934 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2024 Filed May 15, 2024 15:21 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | PurchaseCommon Stock | 296,882 | $1.30 | $385,946.60 |
DisclosureSEC source: 0001373604-24-000022 · form4.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 4,768,262 F3 · price: Purchased in multiple transactions with a weighted average price of $1.30. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2024 Filed May 16, 2024 12:58 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 335,000 | $1.54 | $515,900.00 |
DisclosureSEC source: 0001373604-24-000028 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,672,194 F3 · price: Purchased in multiple transactions with a weighted average price of $1.54. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2024 Filed May 16, 2024 12:58 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 79,281 | $1.56 | $123,678.36 |
DisclosureSEC source: 0001373604-24-000028 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 2,337,194 F2 · price: Purchased in multiple transactions with a weighted average price of $1.56. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 13, 2024 Filed May 15, 2024 15:21 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | PurchaseCommon Stock | 216,053 | $1.26 | $272,226.78 |
DisclosureSEC source: 0001373604-24-000022 · form4.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 4,471,380 F2 · price: Purchased in multiple transactions with an weighted average price of $1.26. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 13, 2024 Filed May 15, 2024 15:21 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | PurchaseCommon Stock | 253,700 | $1.24 | $313,319.50 |
DisclosureSEC source: 0001373604-24-000022 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 4,255,327 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2024 Filed Mar 25, 2024 11:05 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | PurchaseCommon Stock, par value $0.001 per share | 170,589 | $2.95 | $503,237.55 |
DisclosureSEC source: 0001373604-24-000010 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 3,654,053 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 16:19 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | PurchaseCommon Stock, par value $0.001 per share | 113,777 | $3.01 | $342,468.77 |
DisclosureSEC source: 0001373604-24-000006 · form4.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Holding of BML Investment Partners, L.P Disclosed balance after: 3,483,464 F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 00:49 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 1,250,000 | $4.00 | $5,000,000.00 |
DisclosureSEC source: 0001567619-23-000371 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 1,767,774 F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:03 UTC Amendment | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 1,250,000 | $4.00 | $5,000,000.00 |
DisclosureSEC source: 0001567619-23-000570 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 1,767,774 F2 · date: This form was filed to correct the transaction date to 1/3/2023. F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 22:42 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 20,000 | $4.04 | $80,800.00 |
DisclosureSEC source: 0001567619-22-022154 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F2 · price: The shares were sold in multiple transactions at $4.04. Full information regarding the number of shares sold can be furnished to the SEC staff upon request. Read SEC document |
| December 29, 2022 Filed Dec 29, 2022 22:43 UTC | RETRACTABLE TECHNOLOGIES INC RVP · Entity 7624 | SaleCommon Stock | 3,000,000 | $1.60 | $4,800,000.00 |
DisclosureSEC source: 0001567619-22-022102 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 688,575 F2 · price: The shares were sold in one negotiated transaction at $1.60. F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 29, 2022 Filed Dec 29, 2022 23:18 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 19,843 | $4.04 | $80,165.72 |
DisclosureSEC source: 0001567619-22-022103 · doc1.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F2 · price: The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request. Read SEC document |
| December 28, 2022 Filed Dec 29, 2022 23:18 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 157 | $4.04 | $634.28 |
DisclosureSEC source: 0001567619-22-022103 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,843 Read SEC document |
| December 23, 2022 Filed Dec 27, 2022 14:34 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 48,922 | $4.06 | $198,623.32 |
DisclosureSEC source: 0001567619-22-022014 · doc1.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 F2 · price: The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 14:34 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | SaleCommon Stock | 1,078 | $4.06 | $4,376.68 |
DisclosureSEC source: 0001567619-22-022014 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,922 Read SEC document |
| December 21, 2022 Filed Dec 21, 2022 22:49 UTC | Metacrine, Inc. MTCR · Entity 115177 | PurchaseCommon Stock | 120,099 | $0.40 | $48,039.60 |
DisclosureSEC source: 0001567619-22-021933 · doc1.xml · nonDerivative · entry 3 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 6,160,570 F4 · price: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 22:49 UTC | Metacrine, Inc. MTCR · Entity 115177 | PurchaseCommon Stock | 50,122 | $0.38 | $19,001.25 |
DisclosureSEC source: 0001567619-22-021933 · doc1.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 6,040,471 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 22:49 UTC | Metacrine, Inc. MTCR · Entity 115177 | PurchaseCommon Stock | 101,384 | $0.40 | $40,553.60 |
DisclosureSEC source: 0001567619-22-021933 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 5,990,349 F2 · price: The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 23:38 UTC | ASTROTECH Corp ASTC · Entity 7805 | PurchaseCommon Stock | 190,971 | $0.34 | $65,598.54 |
DisclosureSEC source: 0001567619-22-021236 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P.(1) Disclosed balance after: 6,612,311 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions between $0.3349 and $0.35. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F1 · ownership.nature: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 01:14 UTC | RETRACTABLE TECHNOLOGIES INC RVP · Entity 7624 | SaleCommon Stock | 250,000 | $2.00 | $500,000.00 |
DisclosureSEC source: 0001567619-22-021070 · doc1.xml · nonDerivative · entry 2 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,688,575 F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 28, 2022 Filed Dec 1, 2022 01:14 UTC | RETRACTABLE TECHNOLOGIES INC RVP · Entity 7624 | SaleCommon Stock | 2,400 | $2.30 | $5,524.08 |
DisclosureSEC source: 0001567619-22-021070 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P. Disclosed balance after: 3,918,575 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.30 to $2.31. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F1 · ownership.direct: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. F1 · ownership.nature: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 16:02 UTC | ASTROTECH Corp ASTC · Entity 7805 | PurchaseCommon Stock | 75,000 | $0.33 | $24,652.50 |
DisclosureSEC source: 0001567619-22-020878 · doc1.xml · nonDerivative · entry 1 Leonard Braden Michael · CIK 0001373603 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Holding of BML Investment Partners, L.P.(1) Disclosed balance after: 6,421,340 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions between $0.3221 and $0.347. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F1 · ownership.nature: 1. BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.